一、公司概况与市场表现信达生物(01801。HK)是一家致力于成为国际一流生物制药公司的创新药龙头企业,主要覆盖肿瘤、心血管代谢、自身免疫及眼科领域。截至2025年7月23日,公司股价为88港元,市值653.50亿元。公司商业化能力逐步显现,2024年产品销售收入达到82亿元,同比增长44%,并首次实现Non-IFRS利润和EBITDA转正,分别为3.3亿和4.1亿元人民币。二、研发管线与产品...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.